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6The management of tetralogy of 
Fallot after corrective surgery
 ■ RV hypertrophy and a rightward positioned overriding 
aorta. 
 ■ Multi-level pulmonary stenosis with its most extreme 
expression being pulmonary arterial hypoplasia and/or 
pulmonary atresia (Figure 1).(2,3) Other associated anomalies 
are outlined in Table I.
This anatomic constellation was first described by Etienne-
Louis Fallot in 1888.(2) However, it was only 5 decades later 
that progress was made in its physiologic and anatomic treat-





Tetralogy of Fallot (TOF) affects approximately 35 per 100 000 
live births.(1) Its quintessential features result from antero-
cephalad displacement of the outlet septum: 
 ■ Large anterior malaligned ventricular septal defect (VSD).
 ■ Right ventricular (RV) outflow tract obstruction (RVOT).
With the success of contemporary medical and surgical 
management in congenital heart disease (CHD), adults 
with repaired CHD now often outnumber their paedi-
atric equivalents. Tetralogy of Fallot (TOF) has paved 
the way, not only in the management of native CHD, 
but also in the management of its repaired form. 
In this review, we discuss the current surveillance and 
management of adults with repaired TOF, highlighting 
outcomes related to these practices.   
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FIGURE 1: The 3 common subtypes of anterior malaligned VSDs in tetralogy of Fallot are displayed.
A: Perimembranous outlet being the most common;
B: Followed by muscular outlet; and
C: Doubly committed with perimembranous extension. 
In all types, the outlet septum, whether muscular (A and B) or a fibrous remnant (C), is deviated anteriorly causing subvalvar pulmonary 
obstruction. In the perimembranous defects, the conduction system resides along the posterior and inferior margins of the defect where there 
is fibrous continuity between the aortic and tricuspid valves, an important consideration during surgical repair. We are indebted to Professor 
Robert Anderson for kindly sharing these images.
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function in a greater proportion. Adoption of this technique 
has not, however, been uniform. The European Association of 
Cardio-Thoracic Surgery Congenital Database showed that 
only a sixth of surgeons, despite favourable anatomy, use the 
trans-atrial approach.(8)
LATE ANATOMIC AND PHYSIOLOGIC 
OUTCOMES
Right ventricular and outfl ow dysfunction
The surgical evolution of intracardiac repair has led to a 
spectrum of morphologic aberrations in the RV outflow 
combined with functional impairment. Pulmonary regurgita-
tion, stenosis, or a combination of both, are the most common 
late manifestations of this RV outflow morphologic derange-
ments. Pulmonary valve replacement therefore has become 
the most frequent late procedure. In a contemporary cohort, 
approximately one fifth required pulmonary valve replacement 
at a mean age of 20 ±13 years.(9) Hickey and colleagues 
reported the need for additional surgery, as summarised in 
Table II.(10) 
Though well tolerated in the childhood years, pulmonary 
regurgitation usually leads to progressive RV dilation and 
dysfunction and may affect left ventricular function (Figure 2). 
Restrictive RV physiology, defined by the presence of end 
diastolic forward flow in the pulmonary artery coincident with 
atrial contraction, is most often protective against RV dilation 
in the presence of PR and tends to promote better exercise 
capacity.(11) 
The contractile response to exercise of both the RV (and left 
ventricle [LV]) are abnormal in repaired TOF, showing marked 
blunting of isovolumetric contraction as the exercise demand 
increases.(12) There appears to be no significant correlation 
between these contractile responses and RV or LV volumes.
the enormous strides that have transformed the intra-cardiac 
management of all complex congenital cardiac defects over the 
past 70 years. This article focuses on the late post-surgical 
management of the condition. 
SURGICAL MANAGEMENT OF TETRALOGY OF 
FALLOT AND OUTCOMES
The advent of surgical treatment arose from the simple, yet 
profound, observation that cyanosis was caused by diminished 
pulmonary blood flow. Helen Taussig, collaborating with 
Alfred Blalock and Vivien Thomas, created the first successful 
arterial shunt diverting subclavian arterial flow to the pul-
monary artery.(4)
Lillehei reported the first complete intracardiac repair of TOF 
in 1954 utilising a large RV incision and transannular patch.(5) 
This was done under support of the earliest form of cardio-
pulmonary bypass known as “cross-circulation” between a 
father and son. Subsequent cardiopulmonary bypass sciences 
harnessed bubble and membrane oxygenation sciences and 
made intracardiac repair more feasible.
The late outcomes of Lillehei’s original surgical cohort is 
instructive. It demonstrated persuasively the need for long term 
follow-up. Among the first 105 successful operations, patient 
survival at 10, 20 and 30 years were 92%, 80% and 77% 
respectively. Nine percent required late reoperations for 
(i) residual VSD, (ii) RV outflow tract malfunction (stenosis or 
regurgitation), (iii) atrial septal defect and/or (iv) tricuspid 
regurgitation. Lillehei also demonstrated that sudden death, 
occurring in 5%, was part of the surgically modified history. 
The trans-atrial anatomic repair of 1963,(6) was popularised by 
Roger Mee, reporting a mere 0.5% operative mortality and a 
47 month survival of 97.5%.(7) The strength of these new 
approaches lay largely in their minimalist approach to the RV 
outflow tract, conserving pulmonary valve and infundibular 
TABLE 1: Associated anatomic features.
Anomaly Prevalence in TOF
Coronary Anomaly (most common - left anterior 
descending from RCA)
5%
Pulmonary artery origin from the ascending aorta 0.4%
Atrioventricular septal defect 2% - 10%
Absent pulmonary valve syndrome 3% - 6%
Double outlet Right ventricle 4%
TABLE 1I: The need for late re-intervention.
Haemodynamic burden Prevalence 
Pulmonary regurgitation 16% - 20%
RV hypertension needing pulmonary 
arterial intervention
9%
Conduit replacement and/or aneurysm surgery 9%
Tricuspid regurgitation 3%
Residual or recurrent ASD or VSD 9%
Aortic valve replacement 1%
8FIGURE 2: Physiologic consequences of pulmonary regurgitation. This fi gure was adapted from the cited reference by Tal Geva.(34)
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LEFT VENTRICULAR DYSFUNCTION AND 
HEART FAILURE
LV dysfunction occurs in up to 20% of repaired TOF patients, 
with a third of these having moderate or severe dysfunction.(19) 
The underlying etiology is not always evident. Potential causes 
include: surgical coronary arterial injury or compression, longer 
arterial shunt duration, poor myocardial protection, LV vents 
at the time of surgery and acquired coronary vascular disease. 
LV dysfunction most often coexists with RV dysfunction and 
dilation, with frank LV systolic and diastolic dysfunction often 
preceded by abnormal (counterclockwise) rotation of the LV 
base which is likely secondary to these adverse interventricular 
interactions.(20) In those with RV dilation and dysfunction due 
to pulmonary regurgitation, when pulmonary competence is 
restored, LV function often improves.(21) This is most marked in 
those with the worst LV function prior to PVR, in whom LV 
ejection fraction may improve as much as 15%. 
AORTIC ROOT DILATION
Progressive aortic root dilation is common late after TOF 
repair. It is likely due to a combination of intrinsic aortopathy 
(cystic medial degeneration) and haemodynamic factors related 
to greater stroke volume through the aorta.(22) The risk of 
dissection is small, and has generally prompted more permissive 
dimensions as surgical thresholds in clinical practice.(23) 
CLINICAL ASSESSMENT
Clinical assessment should include a detailed review of the 
surgical as well as current history and functional capacity. A 
Diagnostic considerations 
Right and left ventricular function can be tracked on echo-
cardiography by tricuspid or mitral annular plane systolic 
excursion (TAPSE or MAPSE), respectively, RV fractional area 
change, longitudinal strain and right or left ventricular rate of 
pressure rise in early systole (dP/dt), as assessed by the tri-
cuspid or mitral regurgitation Doppler envelope, in any com-
bination. Significant pulmonary regurgitation is identified by 
the presence of a combination of pressure half time (PHT) 
<100ms and pulmonary regurgitation jet width/annulus ratio 
≥1/3, and the presence of diastolic reversal of flow in the 
branch pulmonary arteries.(13)
TRICUSPID REGURGITATION
Some degree of tricuspid regurgitation is common in adults 
with repaired TOF, often related to annular dilation, especially 
in those requiring pulmonary valve replacement (PVR). In fact, 
most major cardiovascular society guidelines include moderate 
or greater tricuspid regurgitation as an indicator for surgical 
PVR in the setting of significant pulmonary regurgitation or 
stenosis,(14) as significant tricuspid regurgitation is associated 
with poor outcomes.(15,16) The jury is hung as to what threshold 
of significant tricuspid regurgitation and annular dilation may 
warrant the addition of tricuspid valve repair at the time of 
PVR.(17) What has been clearly demonstrated is that in the 
majority of patients with tricuspid regurgitation, the severity 













history of recurrent arrhythmia should be obtained. Physical 
examination should elicit signs of 22q11 deletion syndrome on 
general examination. On cardiovascular examination, signs of 
RV dilation and/or hypertrophy, congestive right heart failure, 
pulmonary and tricuspid regurgitation, and the nature of the 
second heart sound, i.e. whether a P2 component is present 
at all, should be sought. Typical CXR and ECG features are 
demonstrated in Figures 3 and 4.
FUNCTIONAL CAPACITY
Cardiopulmonary exercise capacity is usually only mildly 
reduced in 40% of TOF patients during late follow-up. Less 
than one tenth have severe limitation in exercise capacity 
(Figure 5).(24) This reduction in percent of predicted exercise 
capacity is a powerful and independent predictor of mortality 
or ventricular tachycardia (VT). Functional decline over time 
seems to parallel that of the normal population.
ARRHYTHMIA, SUDDEN CARDIAC DEATH AND 
RISK STRATIFICATION
Arrhythmia and sudden cardiac death are recognised late 
sequelae of surgically repaired TOF individuals, occurring at 
approximately 0.2% per year with a late overall prevalence of 
up to 10%.(25) Risk stratification is therefore an important part 
of meaningful late follow-up and management (Table III).(26) 
The strongest independent predictor of late sudden events, 
however, seems to be LV dysfunction and a high LV end-
diastolic pressure (Figure 6). Those at highest risk should 
be considered for invasive haemodynamic assessment with 
programmed ventricular stimulation to identify sustained VT 
(Table IV). The positive and negative predictive value of 
inducible ventricular tachycardia and/or ventricular fibrillation 
(VF) is reported to be 55% and 91% respectively.(27) VT/VF 
FIGURE 3: CXR features of tetralogy of Fallot. 
A prominent pulmonary trunk is evident, with a left aortic 
arch and normal pulmonary vascularity in this case. Sternal 
wires are not visible.
FIGURE 4: ECG features of repaired tetralogy of Fallot.
Broad right bundle branch block with ventricular ectopy. Sometimes RV hypertrophy and right atrial enlargement coexist.
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FIGURE 6: Mean actuarial annualised rates of appropriate implantable cardioverter-defi brillator shocks in primary prevention according to 
clinical characteristics, with elevated left ventricular end-diastolic pressure being the most predictive for appropriate shocks. The mean is 
represented by the black diamonds, bound by the lower and upper 95% confi dence limits. The vertical dotted line represents the actuarial 
annualised rate of appropriate shocks in all primary prevention patients. RV; right ventricle.(28)
Annual rate of appropriate ICD shock (%)
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risk in high risk populations occurs at 3.6% per year.(28) VT 
often arises from the RV outflow in the region of the RV 
outflow patch and the VSD. The anterior wall of the RV outflow 
forms a critical part of the VT circuit, as well as the septal 
surface of the RV free wall through the outlet (infundibular or 
conal) septum. Scar burden may extend well beyond these 
areas, especially in more diseased RVs.(29) Atrial arrhythmias 
have an overall prevalence of 20% (including atrial re-entrant 
tachycardia and atrial flutter) in repaired TOF patients, with 
atrial fibrillation occurring in approximately 7%.(30) 
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FIGURE 5: Cardiopulmonary exercise capacity in patients with repaired TOF, as assessed by percentage of predicted 
peak oxygen uptake. 
Although many patients will have some degree of exercise intolerance, less than one tenth will have severely impaired exercise tolerance.(26)
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Late survival is also influenced by the original anatomic sub-
type. For example, those with atrioventricular septal defects 
and TOF, or TOF and pulmonary atresia, appear to have the 
poorest late survival outcomes.(10) 
Management considerations
Ventricular tachycardia management now generally includes 
AICD as part of the strategy in addition to ablation where 
possible. Arrhythmia surgery is another strategy and can be 
performed at the time of PVR. See below for recommendation 
from PACE/HRS expert consensus statement.(31) 
MANAGEMENT OPTIONS
Indications for surgical and transcatheter 
pulmonary valve replacement
The major cardiovascular society guidelines for timing of surgical 
PVR are summarised in Table V. The focus has historically 
been on RV systolic function and volumetric criteria.(23,32,33) 
More recent treatment strategies favour earlier intervention in 
an attempt to improve RV functional recovery, and perhaps 
late patient survival.(14,34-36) Summarised in Table VI on page 14 
is our own criteria for intervention.
Percutaneous treatment has emerged as a vital and readily 
accessible treatment for patients with pulmonary regurgitation 
and/or stenosis, meeting criteria for intervention. Treatment of 
RVOT outflow diameter ≥16mm and up to 31mm is now 
feasible including the treatment of both native RVOT substrates, 
and undersized homografts.(14) Medtronic’s new Harmony valve 
promises to extend that spectrum even further, allowing treat-
ment of much larger RVOT diameters (Figure 7).(37) 
MEDICAL MANAGEMENT OF TETRALOGY OF 
FALLOT DURING LATE FOLLOW-UP
TOF, not unlike other forms of congenital heart disease, 
demonstrates neurohormonal activation, prompting conven-
tional heart failure approaches to pulmonary regurgitation and/
or tricuspid regurgitation. In a double-blinded, placebo-con-
trolled study, Ramipril taken over a 6 month period in clini-
cally stable patients with repaired TOF and associated 
moderate, to severe, pulmonary regurgitation failed to demon-
strate improved values of ANP, BNP nor CMR – derived RV 
ejection fraction.(38) RV and LV long-axis function did, however, 
improve significantly. Those with restrictive RV physiology 
showed lower LV end-systolic volume indices and an increase 
in LV ejection fraction. Beta-blockers, specifically Bisoprolol, in 
TABLE III: Risk stratification of arrhythmia and sudden 
cardiac death.
Risk Factor Hazard Ratio OR Exp (B) 
Prior palliative shunt HR, 2.6 mortality
Inducible sustained VT HR, 2.1 mortality
QRS duration >180ms HR, 2.0 mortality
Ventriculotomy incision HR, 2.4 mortality
LVEDP ≥12 mmHg HR, 15 mortality
Non-sustained VT HR, 2.7 mortality
RV hypertension per 1mmHg HR, 1.06 mortality
Pulmonary hypertension per 1mmHg HR, 1.16 mortality
LVEDP per 1mm Hg above 12mmHg HR, 1.34 mortality or VT
Peak VO2 <63% of predicted Sensitivity 82%, specifi city 
63% for predicting 5 year 
mortality
Combination QRS >170 + Peak VO2 <65% HR 11.4, mortality
Combination of  QRS >170ms +Peak 
VO2<65% + VE/VCO2 ratio >31
HR 5.4 of combined 
endpoint Mortality, VT, or 
hospitalisation
Transannular patch 1.08
LV = left ventricle, LVEDP = LV end-diastolic pressure, PVC = premature ventricular 
contraction, RV = right ventricle, VE/VCO2 = minute ventilation/carbon dioxide 
production, VO2 = oxygen consumption, VT = ventricular tachycardia.
TABLE 1V: Arrhythmia surveillance.
Heart Rhythm Society ACHD 2014
Coronary artery evaluation is indicated in assessing life threatening ventricular 
arrhythmias or resuscitated SCD in adults with CHD over 40 years of age and 
in those with CHD associated with a higher risk of coronary ischaemia, such as 
(i) congenital anomalies of the coronary arteries, (ii) coronary arteriovenous 
fi stulae, (iii) a history of coronary surgery or (iv) the potential for coronary 
compression by vascular conduits or stents (IB).
EP testing is indicated in adults with unexplained syncope and “high-risk” 
CHD substrates associated with primary ventricular arrhythmias or poorly 
tolerated atrial tachyarrhythmias, such as (i) tetralogy of Fallot, (ii) transposition 
of the great arteries with atrial switch surgery or (iii) signifi cant systemic or 
single ventricular dysfunction (IC).
Surveillance for adults with moderate or severe CHD should include a standard 
12-lead ECG at least once per year (IC).
Periodic Holter monitoring can be benefi cial as part of routine follow-up in 
adults with (i) transposition of the great arteries and atrial switch surgery, 
(ii) Fontan palliation and (iii) tetralogy of Fallot over 35 years of age (IIA-B). 
Programmed ventricular stimulation can be useful in risk stratifying adults with 
TOF who have additional risk factors for SCD such as (i) LV systolic or diastolic 
dysfunction, (ii) non-sustained ventricular tachycardia, (iii) QRS duration >80ms 
and (iv) extensive RV scarring (IIA-B).
ICD therapy is reasonable in selected adults with TOF and multiple risk factors 
for SCD, such as (i) LV systolic or diastolic dysfunction, (ii) non-sustained 
ventricular tachycardia, (iii) QRS duration >180 ms, (iv) extensive right 
ventricular scarring or (v) inducible sustained ventricular tachycardia at EP 
study (IIA-B).
CHD = congenital heart disease, ECG = electrocardiogram, EP = electrophysiology, 
LV = left ventricle, RV = right ventricle, SCD = sudden cardiac death.
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TABLE V: Summary of current guidelines for the late surveillance and management.
ACC/AHA ACHD 2008 CCS 2009 GUCH 2010
General 
Management
Annual (at least) follow up recommended with an 
ACHD cardiologist (I-C).
Patients who require surgery for TOF should 
be operated on by congenital heart surgeons 
(I-C).
Catheterisation should be performed in regional 
centres with expertise in ACHD (IC).
Patients who require reoperation for TOF 
should be operated on by congenital heart 
surgeons (IIA-B).
Surgeons with training/expertise in CHD should 
perform operations (IC).
Genetic screening (i.e. 22q11deletion) should be 
offered to all patients (I-C).
Indications for 
intervention        
PVR is indicated for severe PR and symptoms or 
decreased exercise tolerance (I-B).
The following situations may warrant 
intervention after repair :
AVR should be performed in patients 
with severe AR with symptoms or 
signs of LV dysfunction (I-C).
PVR is reasonable in the setting of severe PR and any 
of the following:
A. Moderate to severe RV dysfunction (IIA-B).
B. Moderate to severe RV enlargement (IIA-B).
C.  Symptomatic or sustained atrial and/or ventricular 
arrhythmia (IIA-C).
D. Moderate to severe TR (IIA-C).
I. Free PR associated with:
A.  Progressive or moderate to severe RV 
enlargement (RVDEV greater than 
170mL/m2).
B. Moderate  to severe RV dysfunction.
C. Important TR.
D.  Atrial or ventricular arrhythmias.
E.  Symptoms such as deteriorating exercise 
performance (IIA-C).
PVR should be performed in 
symptomatic patients with severe PR 
and/or PS (RV systolic pressure 
>60mmHg, TR velocity >3.5 m/s) (I-C).
Coronary artery anatomy (specifi cally the possibility of 
an anomalous anterior descending coronary artery 
across the RVOT) should be ascertained before 
surgery (I-C).
II.  Residual VSD with a shunt greater than 
1.5:1 (IIA-C).
III.  Residual PS with RV pressure at least 
two-thirds the systemic pressure (either the 
native RV outfl ow or valved conduit if one 
is present) (IIA-C).
PVR should be considered in 
asymptomatic patients with severe PR 
and/or PS when at least one of the 
following is present:
A. Decrease in objective exercise 
capacity.
B. Progressive RV dilation.
C. Progressive RV systolic dysfunction.
D. Progressive TR (at least moderate).
E.  RVOT obstruction with RV systolic 
pressure >80mmHg (TR velocity 
>4.3 m/s).
F.  Sustained atrial/ventricular 
arrhythmias (IIA-C for all).
Surgery is reasonable for residual RVOT obstruction 
(valvar or subvalvar) and any of the following:
A.  Peak RVOT gradient on echo greater than 
50mmHg (IIA-C).
B.  RV/LV pressure ratio greater than 0.7 (IIA-C).
C.  Progressive and/or severe RV dilatation with RV 
dysfunction (IIA-C).
D.  Residual VSD with a left-to-right shunt greater than 
1.5:1 (IIA-B).
E.  Severe AR with associated symptoms or more than 
mild LV dysfunction (IIA-C).
F.  Combination of multiple residual lesions 
(i.e. VSD and RVOT obstruction) leading to RV 
enlargement or dysfunction (IIA-C).
IV.  Signifi cant AI associated with symptoms 
and/or progressive LV systolic dysfunction 
(IIA-C).
V.  Aortic root enlargement of at least 5.5cm 
in diameter (IIA-C).
VI.  A large RVOT aneurysm or evidence of 
infection or false aneurysm (IIA-C).
VII.  Sustained clinical arrhythmias, (most 
commonly atrial fl utter or fi brillation and 
sustained monomorphic ventricular 
tachycardia). When any of these occur, the 
patient should also be evaluated for a 
treatable hemodynamic cause of the 
arrhythmia (IIA-C).
VSD closure should be considered in 
patients with residual VSD and 
signifi cant LV volume overload or if the 
patient is undergoing pulmonary valve 
surgery (IIA-C).
Interventional catheterisation is indicated for : 
A.  Elimination of residual native or palliative systemic – 
pulmonary artery shunts (I-B).
B.  Management of coronary artery disease (I-B).
VIII.  The combination of residual VSD and 
residual PS or PR that are all mild-
moderate in severity but leading to 
substantial RV enlargement, RV 
dysfunction or symptoms (IIA-C).
Interventional catheterisation is reasonable for:
A.  Elimination of residual ASD or VSD with a 
left-to-right shunt greater than 1.5:1. It at an 
appropriate anatomic location (IIA-C).
Arrhythmia 
Assessment
Periodic Holter monitoring can be benefi cial. 
Frequency should be individualised depending on 
haemodynamics and clinical suspicion of arrhythmia 
(IIA-C).
Patients who have experienced ventricular 
tachyarrhythmias and/or have been 
resuscitated from sudden cardiac death of no 
clearly identifi ed reversible cause should 
undergo ICDs for secondary prevention (I-B).
Patients deemed to be at particularly high risk 
for sudden cardiac death may benefi t from 
ICDs for primary prevention (IIA-B).













TABLE VI: Suggested criteria for Intervention. We have 
adopted the following criteria for PVR (both surgical and/or 
percutaneous) in our clinical practice: Interventional criteria are 
fulfilled when there is more than moderate pulmonary regurgitation 
or stenosis and 2 additional criteria.
Criteria Value 
Pulmonary regurgitation >= 25%
RVEDVi >150cc/m^2
RVSEVi >80cc/m^2
RV EF <45% or >= moderate dysfunction
RVOT obstruction RVSP >=2/3 systemic pressure
Tricuspid regurgitation >= moderate
QRS duration >160ms
Arrhythmia New onset atrial fl utter, atrial tachycardia 
or fi brillation, or ventricular tachycardia
Exercise capacity <17ml/kg/min 
LV EF <50%
Branch PA stenosis <30% fl ow to affected side
Large RVOT aneurysm
EF = ejection fraction, LV = left ventricle, PA = pulmonary artery, RV = right 
ventricle, RVEDVi = right ventricular end diastolic volume indexed, RVESVi = right 
ventricular systolic volume indexed, RVOT = right ventricular outflow tract.
FIGURE 7: Valves used for percutaneous PVR.
A: Sapien valve. B: Sapient XT valve. C: Sapien 3 valve. D: Melody valve. E: Harmony valve.
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33 TOF patients with residual pulmonary regurgitation or 
pulmonary stenosis and NYHA class I-II heart failure symptoms 
over 6 months showed no significant effect on NYHA class, 
exercise capacity, RV or LV volumes nor ejection fraction by 
CMR.(39) BNP and ANP levels increased when compared to 
patients receiving placebo. This preliminary data discourages 
systematic use of beta-blockers in this population.
THE ROLE OF BNP IN LATE FOLLOW-UP
BNP may be helpful in late surveillance of TOF. In a recently 
published prospective study of patients with repaired TOF, 
compared to a smaller group of age- and gender-matched 
controls, elevated BNP was common in repaired TOF patients 
independent of the degree of pulmonary regurgitation, CMR-
derived metrics or exercise capacitance, being significantly 
related to increased mortality as well as a predictor of sus-
tained arrhythmia. A BNP value ≥15pmol/L was associated with 
a fivefold increased risk in death.(40) This data suggests that 
the monitoring of BNP may be helpful in risk stratification 
during late follow-up.
SURGICAL AND TRANSCATHETER OUTCOMES
Improved surgical management during the initial repair in 
infancy has led to remarkable outcomes, minimal if any 
morbidity or mortality in the first 2 decades of life. However, 
the incidence of impaired functional status, heart failure, 
arrhythmias and death nearly triples during the third post-
operative decade.(10,34,41,42) This period is when patients are 
commonly considered for either surgical or percutaneous PVR 
using the general guidelines for determining the proper timing 
as highlighted above. Considering the short-term outcomes 
following surgical PVR, a recent review of The Society of 
Thoracic Surgeons Congenital Heart Surgery Database (STS-
CHSD) (median age of 17 years) and Adult Cardiac Surgery 
Database (STS-ACSD) (median age of 41 years) reported a 
low risk of in-hospital death (<1%) and major complications 
(~2%) in the younger cohort. The patients in the STS-ACSD 
were older with a higher prevalence of pre-operative risk 
factors and, not surprisingly, had a higher incidence of major 
complications (21%) and in-hospital mortality (4%).(41)
Following surgical PVR there is often a reduction in RV volumes 
and a subjective improvement in functional status.(43-46) Dis-
couragingly, RV systolic dysfunction tends not to improve, and 
more importantly, an improvement in outcomes has not 
been demonstrated.(36) Intermediate- to long-term follow-up 
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has now demonstrated that although there may be early 
improvement in RV volume, pre-operative volumes often 
return by approximately 7 to 10 years following surgical PVR. 
These findings should not dissuade providers from recom-
mending surgical or transcatheter PVR as recommended by 
the current guidelines, but should instead highlight that guide-
lines may be missing important variable(s) that should be 
considered. Recent reports have highlighted that factors, such 
as the important role of the LV, diastolic function, subclinical 
systolic dysfunction as assessed by deformation imaging, exer-
cise imaging and assessment of ventricular fibrosis (both 
replacement and interstitial) may be important considerations 
in better determining the timing for PVR.(14) 
Transcatheter PVR has emerged as a feasible alternative to 
surgical PVR in a large proportion of patients. Initially instated as 
a procedure to prolong the need for surgical PVR, and only 
intended to be used in patients with RV to pulmonary artery 
conduits, it is now often pitted against surgical PVR as an 
alternative therapy, and more commonly being used in native 
outflow tracts. The appeal of avoiding cardiopulmonary bypass 
and a repeat thoracotomy may lend to a more aggressive 
approach, although surgical PVR guidelines for timing are often 
applied.(14) Intermediate outcomes (up to 7 years following 
implant) in the Melody PVR Investigational Device Exemption 
trial has reported good outcomes, with low procedure-related 
morbidity, symptomatic improvement and excellent freedom 
from re-intervention or explant.(47) Short-term complications 
are rare, but may include complications related to vascular 
access, coronary artery compression and aortic root com-
pression, the latter 2 which are reduced with balloon compli-
ance testing prior to valve implantation. Long-term adverse 
outcomes of stent fracture and endocarditis have raised some 
concerns,(47) however, pre-stenting the conduit has reduced 
the first issue, with appropriate patient selection with adherence 
to antibiotic prophylaxis potentially reducing the second.(14,47)
CONCLUSION
TOF, once a lethal condition, can now be successfully treated 
during early childhood, and late surveillance and management is 
now well established, resulting in excellent outcomes. Emerging 
data suggests multiple factors past the commonly used RV 
volumetric and functional criteria that should be used in sur-
veillance and risk stratification of these patients. 
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